possible to determine the exact concentration in the samples.
Therefore the phase diagram in Fig. 2 has to be understood as a
qualitative description. The samples were examined with a
polarised optical microscope (BHS, Olympus) equipped with a
hot stage (LTS 350, Linkam). Optical properties were measured
using reflectometric interference spectroscopy (Alton Instru-
ments Lambda LS 2000)12 or a l-compensator,13 respectively.
Samples for the X-ray diffraction experiments were prepared
in Mark capillaries (Hilgenberg, 0.7 mm diameter) and measured
with a Bruker Nanostar system applying CuKa radiation
potassium iodide were added, the vessel was sealed and micro-
waved for 2 hours at 100 ꢀC. The solution was filtered, the
solvent was removed and the residue was purified chromato-
graphically (SiO2, 3 : 1 c-Hex/EtOAc, Rf ¼ 0.56) yielding 327 mg
(97%) of 4 as a colourless solid. mp (DSC): Cr 44.4 SmC 59.4 N
60.1 I (from c-Hex–EtOAc). dH (300 MHz, CDCl3) 8.56 (2H, s;
4-H and 6-H), 8.36 (2H, d, J 8.9; 20-H and 60-H), 6.97 (2H, d, J
8.9; 30-H and 50-H), 5.86 (1H, ddt, J 16.9, 10.1, 6.6; 400-H), 5.07
(1H, ddt, J 17.1, 1.7, 1.7; cis-500-H), 5.01 (1H, ddt, J 10.2, 1.5, 1.5;
trans-500-H), 4.04 (2H, t, J 6.4; 100-H), 2.58 (2H, t, J 7.6;
CH2CH2(CH2)4CH3), 2.32–2.18 (2H, m; 300-H), 1.96–1.86 (2H,
m; 200-H), 1.64 (2H, p, J 7.4; CH2CH2(CH2)4CH3), 1.40–1.24
ꢁ
(l ¼ 1.5418 A). Alignment of the samples was achieved by slowly
cooling in a magnetic field (ꢁ1 T) using an integrated tempera-
€
ture controller (TCPU H, MRI Physikalische Gerate GmbH).
(8H, m; CH2CH2(CH2)4CH3), 0.94–0.83 (3H, t, J 6.8;
NMR spectra were recorded on a Bruker DPX 300. Infrared
spectra were obtained using a Perkin-Elmer Paragon 1000 FTIR
spectrometer as ATR signals on a ZnSe crystal. Mass spectra
were taken on a Finnigan MAT Incos 50 Galaxy System (low
resolution), a Finnigan MAT 900 S (high resolution, CI) or a
Bruker Daltonics micrOTOF-Q (high resolution, ESI). CHN-
combustion analyses were measured using an Elementar Vario
EL Instrument. The enantiomeric excess was determined by
analytic HPLC (Daicel Chiralcel OJ, hexane/2-propanol 90 : 10
at 1.00 nl minꢂ1).
CH2CH2(CH2)4CH3). dC (75 MHz, CDCl3) 162.67 (s; C2),
161.26 (s; C40), 157.01 (d; C4 and C6), 137.87 (d; C400), 132.15 (s;
C5), 130.50 (s; C10), 129.56 (d; C20 and C60), 115.31 (t; C500),
114.60 (d; C30 and C50), 67.43 (t; C100), 31.85 (t;
CH2CH2(CH2)3CH2CH3), 30.88 (t; CH2CH2(CH2)3CH2CH3),
30.28 (t; CH2CH2(CH2)3CH2CH3), 30.22 (t; C300), 29.12 (t;
CH2CH2(CH2)3CH2CH3), 28.62 (t; C200), 22.72 (t;
CH2CH2(CH2)3CH2CH3), 14.13 (q; CH2CH2(CH2)3CH2CH3).
nmax/cmꢂ1 3077 (w), 3017 (w), 2994 (w), 2951 (m), 2924 (s), 2853
(m), 1640 (w), 1606 (m), 1583 (s), 1540 (m), 1513 (m), 1467 (m),
1429 (s), 1393 (m), 1327 (m), 1299 (m), 1251 (s), 1167 (m), 1106
(m), 1054 (m), 1028 (m), 991 (m), 935 (m), 910 (m), 845 (m), 822
(w), 796 (s), 759 (w), 721 (w), 701 (w), 653 (m); LRMS (EI, 70 eV)
m/z: 69 (20%) [C5H9+], 119 (12) [C7H4NO+], 158 (19)
[C9H6N2O+], 185 (100) [M+-C6H13-C5H9], 199 (12) [M+-C5H11-
C5H9], 253 (7) [M+-C6H13], 270 (24) [M+-C5H9], 338 (33) [M+].
HRMS (EI, 70 eV) m/z calcd. for C22H30N2O: 338.2358. Found:
338.236. Anal. calcd for C22H30N2O: C, 77.82; H, 8.90; N, 8.21.
Found: C, 78.06; H, 8.93; N, 8.28%.
Synthesis of 5-[4-(5-n-heptylpyrimidine-2-yl)phenoxy]pentane-
1,2-diol
(rac)-500-[40-(5-n-Heptylpyrimidine-2-yl)phenoxy]pentane-1,2-diol
(rac-1) was synthesised according to the procedure described in
ref. 14.
The chiral compound S-1 was obtained by a sequence of
etherification of the commercially available 4-(5-heptylpyr-
imidin-2-yl)phenol (3, Synthon Chemicals GmbH) with 5-bro-
mopent-1-ene followed by an asymmetric dihydroxylation as
outlined in Scheme 1.
(S)-500-[40-(5-n-Heptylpyrimidine-2-yl)phenoxy]pentane-1,2-diol
(S-1). 327 mg (0.97 mmol) of 4 were solved in 7 ml tert-butanol
and dropped slowly into a cooled solution of 1.4 g AD-mix-a 15
in 7 ml water. The reaction mixture was stirred for 72 hours at 6
ꢀC and for 48 hours at room temperature. The mixture was
extracted twice with ethyl acetate, the organic phase was dried
over magnesium sulfate and the solvent was evaporated. The
residue was purified chromatographically (SiO2, EtOAc) yielding
334 mg (0.88 mmol, 93%) of S-1 as a colourless solid; ee 66%. dH
(300 MHz, CDCl3) 8.56 (2H, s; 4-H and 6-H), 8.33 (2H, d, J 8.7;
30-H and 50-H), 6.97 (2H, d, J 8.8; 20-H and 60-H), 4.06 (2H, t, J
5.9; 500-H), 3.87–3.74 (1H, m, 200-H), 3.68 (1H, dd, J 10.9, 3.1; 100-
Ha), 3.48 (1H, dd, J 11.0, 7.5; 100-Hb), 2.85–2.00 (2H, bs; OH),
2.59 (2H, t, J 8.2; CH2CH2(CH2)4CH3), 2.05–1.80 (2H, m; 400-H),
1.77–1.50 (4H, m; 300-H and CH2CH2(CH2)4CH3), 1.44–
5-Heptyl-2-[40-(pent-400-en-100-yloxy)phenyl]pyrimidine (4). In a
sealable 10 ml microwave vessel, 270 mg (1.0 mmol) 4-(5-hep-
tylpyrimidin-2-yl)phenol (3) were solved in 6 ml acetone. 164 mg
(0.13 ml, 1.1 mmol) 5-bromopent-1-ene (2), 460 mg (2.0 mmol)
tripotassium phosphate monohydrate and 17 mg (0.1 mmol)
1.19 (8H, m; CH2CH2(CH2)4CH3), 0.87 (3H, t,
J 6.4;
CH2CH2(CH2)4CH3). dC (75 MHz, CDCl3) 162.50 (s; C2),
160.96 (s; C10), 157.09 (d; C4 and C6), 132.35 (s; C5), 130.48
(s; C40), 129.57 (d; C30 and C50), 114.54 (d; C20 and C60),
71.99 (d; C200), 67.99 (t; C500), 66.91 (t; C100), 31.86 (t;
CH2CH2(CH2)3CH2CH3), 30.94 (t; CH2CH2(CH2)3CH2CH3),
30.27 (t; CH2CH2(CH2)3CH2CH3), 29.98 (t; C300), 29.14 (t;
CH2CH2(CH2)3CH2CH3), 25.58 (t; C400), 22.75 (t;
CH2CH2(CH2)3CH2CH3), 14.21 (q, CH2CH2(CH2)3CH2CH3).
nmax/cmꢂ1 3450 (bw), 2951 (m), 2924 (m), 2853 (m), 2779 (w),
1738 (m), 1667 (w), 1656 (w), 1606 (m), 1583 (m), 1541 (m), 1512
Scheme 1 Synthesis of (S)-500-[40-(5-n-heptylpyrimidine-2-yl)phenoxy]
pentane-1,2-diol (S-1). (a) K3PO4$H2O, KI, acetone, microwave, 100 ꢀC,
2 h, 97% and (b) AD-mix a, t-BuOH, H2O, 6 ꢀC, 72 h, r.t., 48 h, 93%.
18202 | J. Mater. Chem., 2012, 22, 18198–18203
This journal is ª The Royal Society of Chemistry 2012